Hepion Pharmaceuticals, Inc. (HEPA)

NASDAQ: HEPA · IEX Real-Time Price · USD
2.448
+0.108 (4.62%)
At close: Feb 27, 2024, 3:59 PM
2.400
-0.048 (-1.96%)
After-hours: Feb 27, 2024, 6:04 PM EST
4.62%
Market Cap 10.15M
Revenue (ttm) n/a
Net Income (ttm) -47.82M
Shares Out 4.34M
EPS (ttm) -12.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,372
Open 2.420
Previous Close 2.340
Day's Range 2.280 - 2.480
52-Week Range 1.490 - 20.660
Beta 1.40
Analysts Hold
Price Target n/a
Earnings Date Apr 8, 2024

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumo... [Read more]

Industry Biotechnology
Sector Healthcare
CEO John T. Cavan
Employees 25
Stock Exchange NASDAQ
Ticker Symbol HEPA
Full Company Profile

Financial Performance

Financial Statements

News

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug deve...

11 days ago - GlobeNewsWire

Hepion Pharmaceuticals to Present at NASH-TAG 2024

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

7 weeks ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account curren...

2 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

3 months ago - GlobeNewsWire

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat

Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023

3 months ago - GlobeNewsWire

Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

- Rencofilstat, but not sofosbuvir or velpatasvir, significantly suppressed tumor growth - - Rencofilstat, but not sofosbuvir or velpatasvir, significantly suppressed tumor growth -

4 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug dev...

5 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

5 months ago - GlobeNewsWire

Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in liver cancer - EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Hep...

5 months ago - GlobeNewsWire

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

– Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior effects of rencofilstat alone and in combination with pirfenidone and nintedanib – EDISON,...

5 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Management Changes

EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-assisted therapeutic d...

6 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution –

9 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH' Trial of Rencofilstat

EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

9 months ago - GlobeNewsWire

Theralase(R) Announces Appointment of New Independent Director

TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and deve...

9 months ago - Accesswire

Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences

EDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence (“AI”)-assisted therapeutic dru...

9 months ago - GlobeNewsWire

HEPA stock price surged but beware of this glaring Hepion risk

Hepion Pharmaceuticals' (NASDAQ: HEPA) stock price went parabolic on Monday after the company made an important announcement about its mid-stage trial. The shares jumpd by more than 110% and reached a...

10 months ago - Invezz

Hepion Pharmaceuticals' Phase 2 ‘ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence ...

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat

EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split

EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023

EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

11 months ago - GlobeNewsWire

Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs

EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

11 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

1 year ago - GlobeNewsWire

Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress

EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

1 year ago - GlobeNewsWire

EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion's Patent Portfolio

– Patent Covers 38 European Countries –

1 year ago - GlobeNewsWire

Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023

EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

1 year ago - GlobeNewsWire